Ask AI
Tx Selection and Optimization in MCL

CME

Optimizing Mantle Cell Lymphoma Care: Case-Based Guidance From EU Experts

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: May 29, 2026

Expiration: November 28, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Yoon DH, Cao J, Chen TY, et al. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. J Hematol Oncol. 2020;13:21.
  2. Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62-iv71.
  3. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558-565.
  4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: B-cell lymphomas. v.3.2026. nccn.org. Accessed May 26, 2026.
  5. Jerkeman M, Aurer I, Campo E, et al. EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma. Hemasphere. 2025;9:e70233.
  6. Dreyling M, Doorduijn JK, Gine E, et al. Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: results from the randomized Triangle trial by the European MCL Network. Presented at: American Society of Hematology Annual Meeting and Exposition; December 7-10, 2024. Abstract 240.
  7. Wang M, Paludo J, de Holanda Farias JS, et al. Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up. Presented at: American Society of Hematology Annual Meeting and Exposition; December 6-9, 2025; Abstract 885.
  8. Lewis DJ, Jerkeman M, Sorrell L, et al. Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial. Lancet. 2025;406:1953-1968.
  9. Dreyling M, Tam CS, Wang M, et al. A phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncol. 2021;17:255-262.
  10. Hawkes E, Romejko-Jarosinska J, Jurczak W, et al. Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): results from the phase 2 TrAVeRse study. Blood. 2025;146:884.
  11. Merryman RW, Edwin N, Redd R, et al. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020;4:858-867.
  12. Kim A, Riedell P, Ryan C, et al. Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated mantle cell lymphoma (MAVO). Blood. 2025;146:664.
  13. Le Gouill S, Morschhauser F, Chiron D, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 2021;137:877-887.
  14. Kumar A, Soumerai J, Abramson JS, et al. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood. 2025;145:497-507.
  15. Berglof A, Hamasy A, Meinke S, et al. Targets for ibrutinib beyond B cell malignancies. Scand J Immunol. 2015;82:208-217.
  16. Ibrutinib [prescribing information]. Sunnyvale, CA: Pharmacyclics LLC; 2025.
  17. Acalabrutinib [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
  18. Zanubrutinib [prescribing information]. San Mateo, CA: BeiGene USA, Inc; 2025.
  19. Moore DC, Thompson D. A review of the Bruton tyrosine kinase inhibitors in B-cell malignancies. J Adv Pract Oncol. 2021;12:439-447.
  20. Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133:1298-1307.
  21. Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41:3988-3997.
  22. Acalabrutinib [product information]. Cambridge, United Kingdom: AstraZeneca AB; 2025.
  23. Wang M, Jurczak W, Trneny M et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2025;26:200-213.
  24. Brexucabtagene autoleucel [prescribing information]. Frederick, MD: Kite, A Gilead Company; 2020.
  25. Brexucabtagene autoleucel [product information]. Hoofddorp, Netherlands: Kite Pharma EU B.V.; 2019.
  26. Lisocabtagene maraleucel [prescribing information]. Seattle, WA: Juno Therapeutics, Inc.; 2024.
  27. Lisocabtagene maraleucel [product information]. Dublin, Ireland: Bristol Myers Squibb; 2025.
  28. Wang M, Muñoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331-1342.
  29. Wang M, Muñoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41:555-567.
  30. Muñoz J, Locke FL, Reagan PM, et al. Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2. J Hematol Oncol. 2026;[Epub ahead of print].
  31. van Meerten T, Kersten MJ, Iacoboni G, et al. Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3. Blood 2026;147:1302-1314.
  32. Wang M, Siddiqi T, Gordon LI, et al. Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol. 2024;42:1146-1157.
  33. Pirtobrutinib [product information]. Utrecht, Netherlands: Eli Lilly Nederland B.V.; 2021.
  34. Shah NN, Wang M, Roeker LE, et al. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. 2025;110:92-102.
  35. Wang M, Song Y, Hermine O, et al. Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) previously treated with a Bruton tyrosine kinase (BTK) inhibitor: early results from a phase 1/2 study. Blood. 2025;146:663.
  36. Sonrotoclax [prescribing information]. San Mateo, CA: BeiGene; 2025.
  37. Tapia-Galisteo A, Alvarez-Vallina L, Sanz L. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol. 2023;16:83.
  38. Hambleton H and Cheah CY. The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma. Expert Opin Investig Drugs. 2025;34:245-252.
  39. Phillips TJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab in relapsed/refractory mantle cell lymphoma: results from a phase I/II study. J Clin Oncol. 2025;43:318-328.
  40. Ibrutinib [product information]. Beerse, Belgium: Janssen-Cilag International NV; 2026.